comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 18:17:19 - browse：231

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Padmanee Sharma of MD Anderson at center of lawsuit over credit

WSS

Surgery pushed Ben Carson to fame

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Medicare Advantage plans can’t deny care with AI, CMS warns

Venture capital firm's plans to take over Akron hospital face hurdles

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

entertainment

comprehensive

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Hollywood unions extend contract negotiations for actors

Johnson & Johnson sued for allegedly overpaying for workers' drugs

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why Medicare shouldn’t cover every FDA

Duchenne breakthrough therapy leaves behind pioneering families

AI gets buy

Wildfire smoke exposes gaps in outdoor worker protections

Problems with a popular proposal to regulate AI in health care

leisure time

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Merck CEO won’t testify in Senate, citing no expertise in drug prices

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Global cancer cases to surge 77% by 2050, WHO report says

AI gets buy

Johnson & Johnson sued for allegedly overpaying for workers' drugs

focus

entertainment

entertainment

entertainment